The Weight Loss Drug Market in 2024

         

The weight loss drug market is expected to see more changes in 2024 as demand continues to rise, but supply issues persist and new players enter the market.

Rising Demand and Market Expansion

The weight loss drug market saw a surge in popularity in 2023 and is projected to expand even further, potentially reaching a value of $100 billion by the end of the decade. Analysts expect 15 million U.S. adults to be on obesity medications by 2030.

Challenges with Supply and Dominant Players

Novo Nordisk and Eli Lilly, the dominant players in the weight loss drug market, are currently facing supply issues with their treatments. Analysts anticipate these constraints to improve but acknowledge that it could take years for the broader issue to be resolved.

New Drug Data and Potential Health Benefits

The upcoming year may bring new data releases from Novo Nordisk and Eli Lilly, showcasing potential health benefits of their drugs beyond weight loss and diabetes management. These findings could lead to increased insurance coverage in the future.

Competition and Market Landscape Shifts

Other companies such as Pfizer and Amgen are expected to introduce new weight loss drug data, potentially altering the competitive landscape of the market. Collaborations between larger and smaller companies are also anticipated, shaping the future of the industry.

Expectations for Specific Drugs

The weight loss drugs Wegovy, Zepbound, Ozempic, and Mounjaro from Novo Nordisk and Eli Lilly are anticipated to face milestones, supply improvements, and potential expanded uses, contributing to the evolution of the market in 2024.

Pfizer’s Pursuit and External Ventures

Pfizer aims to enter the weight loss drug space with a once-a-day version of its pill, placing high stakes on its success. External acquisitions and partnerships among larger and smaller pharmaceutical companies are expected to influence the market dynamics.

Watch for Buyouts and Partnerships

Various partnerships and acquisitions have already shaped the weight loss drug market, and more are foreseen in the coming year. Large pharmaceutical companies are actively seeking external innovation to strengthen their drug pipelines and maintain competitiveness.

Potential for Future Developments

Overall, the weight loss drug market in 2024 is poised for further growth, driven by ongoing research, advancements in drug offerings, and the pursuit of market opportunities by pharmaceutical companies of all sizes.

Share: